Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +336.38%
#4 aPriori aPriori +129.43%
#5 Bedrock Bedrock +68.55%
#6 Cysic Cysic +48.18%
#7 Prom Prom +41.94%
#8 Playnance Playnance +35.15%
#9 Nillion Nillion +25.56%
#10 Bitway Bitway +25.33%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
Rank in Stocks #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Share Price
$0.00023723
Last synced: 2024-08-26
Market Cap
$1.41K
Change (1 day)
111.67%
Change (1 year)
0.00%
Country
FR
Trade Pharnext S.A. (ALPHA)

Category

Healthcare
P/S ratio for Pharnext S.A. (ALPHA)
P/S ratio as of August 2026 TTM: 0.12
According to Pharnext S.A. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.12. At the end of 2022 the company had a P/S ratio of 17.807T.
P/S ratio history for Pharnext S.A. from 2012 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 0.12 -99.84%
2023 73.60 -100.00%
2022 17.807T -99.54%
2021 3.91Qa -97.44%
2020 152.45Qa 270.01%
2019 41.20Qa 1,356.30%
2018 2.83Qa -40.90%
2017 4.79Qa 24.33%
2016 3.85Qa -46.55%
2015 7.20Qa 4.78%
2014 6.87Qa -4.45%
2013 7.19Qa 0.00%
2012 0.00 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 8,203.19%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 8,557.98%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 4,084.29%
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR